First half consolidated earnings resulted in increased revenues and income compared to the previous year. Overall, the first half transitioned smoothly.
vs. Plan

 • Net sales +0.4% (YoY +0.8%)

Largely on par with plans

 • Operating income +9.0% (YoY +20.9%)

Benefitted from cost control efforts in both Food and Pharmaceutical

 • Net income +20.9% (YoY +29.2%)

Outperformed plans on level exceeding operating income
Foreign exchange gain and gains on sale of fixed assets were not factored into plans.